Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Lymphoid 2Sarcoma 1Plasma cell 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 7Hematologic Neoplasms 4Waldenstrom Macroglobulinemia 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, B-Cell 2Vascular Diseases 1Recurrence 1Paraproteinemias 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasms 1Mature B-cell Neoplasms 1Lymphoproliferative Disorders 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphatic Diseases 1Leukemia, Lymphoid 1Leukemia 1Immunoproliferative Disorders 1Immune System Diseases 1Hemostatic Disorders 1Hemorrhagic Disorders 1Dendritic Cell Sarcoma, Interdigitating 1Cardiovascular Diseases 1Blood Protein Disorders 1

Interventions

Cyclophosphamide 87fludarabine 77fludarabine phosphate 45Tacrolimus 45Whole-Body Irradiation 42Mycophenolic Acid 42Busulfan 35Melphalan 32Antilymphocyte Serum 24Methotrexate 23thymoglobulin 22Standard of Care 22Rituximab 22venetoclax 20Thiotepa 20Sirolimus 20Azacitidine 20Stem Cell Transplantation 18Granulocyte Colony-Stimulating Factor 18Practice Guidelines as Topic 17Cytarabine 16Bortezomib 16Nivolumab 15Filgrastim 15Specimen Handling 14Dexamethasone 14Blood Specimen Collection 14Cyclosporine 13Surveys and Questionnaires 12Mesna 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Hematologic Neoplasms × ARQ531 × Clear all
NCT04728893 2026-05-26

MK-1026-003

Merck Sharp & Dohme LLC

Phase 2 Recruiting
490 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, B-Cell, Hematologic Neoplasms

NCT05347225 2026-04-30

MK-1026-005

Merck Sharp & Dohme LLC

Phase 1 Active not recruiting
12 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT03162536 2025-09-08

ARQ 531-101

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1/2 Active not recruiting
190 enrolled
LymphoidOther hematologic neoplasmPlasma cellSarcoma

Blood Protein Disorders, Cardiovascular Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Lymphoid, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Recurrence, Vascular Diseases, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Hemostatic Disorders, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell, Dendritic Cell Sarcoma, Interdigitating

NCT06586671 2024-09-19

MK-1026-007

Merck Sharp & Dohme LLC

Phase 1 Completed
40 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡